Xeris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Xeris Pharmaceuticals Inc. (XERS) Tops Q3 EPS by 17c, Revenues Beat
November 9, 2020 7:00 AM ESTXeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.35), $0.17 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $4.48 million.
The third quarter results showed the tremendous response from the diabetes community to the... More
